Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 60

Results For "IPA"

1121 News Found

Dr VK Paul delivers lecture at NITI Aayog’s First India Development Strategies Lecture Series
News | October 01, 2022

Dr VK Paul delivers lecture at NITI Aayog’s First India Development Strategies Lecture Series

Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic


LISSUN raises ~$1 million in pre-Seed round from IvyCap Ventures and others
News | September 28, 2022

LISSUN raises ~$1 million in pre-Seed round from IvyCap Ventures and others

Funds raised will be used to develop technology and foster healthcare partnerships


Hester planning capacity expansion for Goat Pox vaccine
News | September 27, 2022

Hester planning capacity expansion for Goat Pox vaccine

Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine


Novartis unveils new focused strategy
News | September 27, 2022

Novartis unveils new focused strategy

Transformation to pure-play Innovative Medicines company nears completion


JB Pharma rolls out its campaign #Heart2HeartChallengeIndia
Healthcare | September 24, 2022

JB Pharma rolls out its campaign #Heart2HeartChallengeIndia

The #Heart2HeartChallengeIndia campaign is very simple – you have to climb 60 steps in a minute, make a video of it, share it on your social media, tag 5 people, inviting them to take this challenge to check their heart health


Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners
Opinion | September 22, 2022

Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners

Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.


Merck to initiate new Phase 3 clinical program for treatment of HIV-1 Infection
Diagnostic Center | September 21, 2022

Merck to initiate new Phase 3 clinical program for treatment of HIV-1 Infection

Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir


Azelis expands pharmaceutical offerings with Clariant
News | September 21, 2022

Azelis expands pharmaceutical offerings with Clariant

Azelis’ customers now have access to products including the well-established Polyglykol portfolio, as well as a brand-new range of Motusflex and VitiPure excipients.


Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19
Drug Approval | September 21, 2022

Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19

Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase III treatment trial